Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) will be issuing its Q3 2017 quarterly earnings data on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.69) per share for the quarter.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.13. On average, analysts expect Tonix Pharmaceuticals Holding Corp. to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) opened at $3.77 on Monday. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $2.85 and a 52-week high of $9.40.
COPYRIGHT VIOLATION NOTICE: “Tonix Pharmaceuticals Holding Corp. (TNXP) Set to Announce Quarterly Earnings on Wednesday” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://stocknewstimes.com/2017/11/06/tonix-pharmaceuticals-holding-corp-tnxp-set-to-announce-quarterly-earnings-on-wednesday.html.
In related news, CEO Seth Lederman acquired 20,000 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was acquired at an average price of $3.00 per share, with a total value of $60,000.00. Following the acquisition, the chief executive officer now directly owns 11,166 shares in the company, valued at approximately $33,498. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.00% of the company’s stock.
An institutional investor recently raised its position in Tonix Pharmaceuticals Holding Corp. stock. Vanguard Group Inc. grew its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 184,377 shares of the company’s stock after buying an additional 41,264 shares during the quarter. Vanguard Group Inc. owned 2.46% of Tonix Pharmaceuticals Holding Corp. worth $799,000 as of its most recent SEC filing. Institutional investors and hedge funds own 22.98% of the company’s stock.
TNXP has been the subject of a number of research reports. ValuEngine raised Tonix Pharmaceuticals Holding Corp. from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Drexel Hamilton initiated coverage on Tonix Pharmaceuticals Holding Corp. in a research report on Tuesday, August 22nd. They set a “buy” rating for the company. Dawson James reaffirmed a “buy” rating and set a $9.00 price target on shares of Tonix Pharmaceuticals Holding Corp. in a research report on Wednesday, August 23rd. Finally, Roth Capital raised Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a report on Friday, August 18th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $8.33.
Tonix Pharmaceuticals Holding Corp. Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.